alexa Clinicopathological and Prognostic Value of Programmed Death Ligand-1 (PD-L1) In Breast Cancer: A Meta-Analysis | OMICS International
Journal of Tumor Research

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Clinicopathological and Prognostic Value of Programmed Death Ligand-1 (PD-L1) In Breast Cancer: A Meta-Analysis

Qi Xue*and Guochao Zhang

Department of Thoracic Surgery, Cancer Hospital of Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China

Corresponding Author:
Qi Xue
Department of Thoracic Surgery
Cancer Hospital of Peking Union Medical College and Chinese Academy of Medical Sciences
Beijing, China
Tel: 008618801038718
E-mail: [email protected]

Received date: August 22, 2017; Accepted date: August 29, 2017; Published date: August 31, 2017

Citation: Xue Q, Zhang G (2017) Clinicopathological and Prognostic Value of Programmed Death Ligand-1 (PD-L1) In Breast Cancer: A Meta-Analysis. J Tumor Res 3:127.

Copyright: © 2017 Xue Q, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Tumor Research


Background: The association of immunological checkpoint marker programmed death ligand-1 (PD-L1) and the prognosis of various malignancies has been widely observed, recently. However, the association between PD-L1 expression and breast cancer patients’ survival remains controversial. Thus, we performed this study to assess the clinical value of PD-L1.

Methods: We searched the electronic databases for eligible literature. Medline/PubMed, EMBASE, the Cochrane Library databases and Grey literature were searched up to 30 March 2016 for the association between PD-L1 expression and breast cancer prognosis. Hazard ratios (HRs) for overall survival (OS) with 95% confidence intervals (CIs) according to the expression status of PD-L1 were calculated from the included studies. Moreover, the odds ratio (OR) was also analyzed to evaluate the association between the clinicopathological parameters of participants and PD-L1 expression.

Results: 10 studies were included in the meta-analysis while 7 for clinical pathological features and PDL1. We found that elevated PD-L1 had no significant association with breast cancer patients’ survival. However, increased PD-L1 was found to be significantly associated with histological grade (OR=1.86, 95% CI: 1.38-2.51; Pheterogenecity=0.0196), ER (OR=0.36, 95% CI: 0.17-0.75; Pheterogenecity=0.000), PR (OR=0.31, 95% CI: 0.11-0.86; Pheterogenecity=0.000) in breast cancer.


PD-L1; Breast cancer; Prognosis; Meta-analysis; Clinicopathological features


Breast cancer is the most common malignant tumor in women around the world [1]. Although recent advances in surgery and adjuvant therapies have improved the prognosis, however, the overall prognosis for metastatic breast cancer patients remains poor. These days, scientists find the development and prognosis of malignant tumors are closely related to host immune functions. In tumor lesion the immune environment is composed of tumor cells, immune cells, cytokines, and stromal cells [2]. We called the immune cells tumor invasive lymphocytes (TIL). The role of healthy immune system in controlling the progression of malignant disease is well established. So the immune escape along with cancer is the major cause of cancer progression [3]. This is considered being connected by PD-L1 (programmed death ligand 1).

PD-L1 is an important immune checkpoint that mediates tumorinduced immune suppression. PD-L1 expression has been observed in various malignancies. Moreover, several meta-analyses have proved that PD-L1 overexpression indicates a poor prognosis for patients with nonsmall cell lung cancer and gastrointestinal tract cancer [4-6]. However, the association between PD-L1 expression and the breast cancer survival of patients remains controversial. PD-L1 usually expressed on tumor cells while, PD-1 (programmed death 1) mostly expressed on tumor-infiltrating lymphocytes [7]. Scientists have conducted some researches on PD-L1 and breast cancer, they found PD-L1 expression is associated with poor clinical and pathological features of breast cancer [8-15]. The main mechanism is reported that PD-L1 inhibit the proliferation of activated T-cells and induce the apoptosis of T-cells to form and maintain an immunosuppressive microenvironment since PD-L1 can recognize and bind the PD-1 on tumor-infiltrating lymphocytes [16]. However, last year, some researchers found PDL1 expression was significantly associated with better OS (p=0.04) in breast cancer patients, including analyzing mRNA expression and using DNA microarray [17,18]. Thus, someone thought PD-L1 expression is considered a positive prognostic biomarker in breast cancer.

Now the prognostic role of PD-L1 in breast cancer is still under debate and requires further comprehensive study to clarify. Thus, we performed a meta-analysis by incorporating all available evidence to reveal the prognostic value of PD-L1 in breast cancer. Meanwhile, analyze the relationship of PD-L1 and the clinical pathological features.

Materials and Methods

Literature search strategy

Two authors of us independently searched for published abstracts and articles. The searched international databases include PubMed, the Cochrane Library databases, EMBASE and Grey literature up to 30 March 2016. The key terms are “PD-L1”, “B7-H1”, “CD274”, “B7 homolog 1” or “programmed death ligand-1” and “breast cancer” and “survival” or “prognosis”. We all manually reviewed relevant manuscripts, conference summaries and reference lists and reviews.

Our institutions Ethics Committee have exempted our study from Institutional Review Board approval as our study involves exclusively preexisting anonymous data. The preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement for reporting systematic reviews recommended by the Cochrane Collaboration was followed for conducting this meta-analysis.

Selection criteria

Studies met the following criteria were eligible for the meta-analysis of PD-L1 expression and breast cancer prognosis, PD-L1 expression and clinicopathological features: (1) data from breast cancer patients; (2) all of the patients were pathologically confirmed; (3) correlation between PD-L1, clinicopathological features and prognosis was described. Articles were excluded from the analyses according to the following criteria: (1) non-English papers; (2) non-human experiments; (3) review articles, case reports or letters; (4) duplicate publication; (5) insufficient data to report the risk ratios (RR) and 95% confidence interval (95% CI).

Data extraction

All data were extracted by two independent reviewers (ZGC&XQ). The quality of the selected articles was assessed according to the Newcastle-Ottawa Scale (NOS) [19]. Data tables were generated to extract all relevant data from texts, tables and figures, including: author, year of publication, country, patient number, cancer type, specimen, detection method, analysis method, the cut-off value, risk ratio, duration of follow-up as well as positive rates of PD-L1 overexpression. OS data were extracted in the form of hazard ratios (HRs) with the corresponding 95% confidence interval (CI). The data collection and assessment of methodological quality followed the quality of reporting of meta-analyses (QUORUM) and the Cochrane Collaboration guidelines ( All investigators discussed and resolved all discrepancies in the extracted data. All of the eligible studies were of high quality.

Statistical analysis

We performed heterogeneity test among different studies using Q test and I2 statistic. The fixed effect model with Mantel and Haenszel method was used to do the Meta analysis, when the P value of Q test>0.05 and the I2<50%. Otherwise, the random effect model with DerSimonian and Laird method was adopted [20,21]. The pooled hazard ratio (HR) and its 95% confidence interval (CI) were estimated to evaluate the prognosis difference of PD-L1+ group and PD-L1- group. The pooled risk ratio (RR) and its 95% confidence interval (CI) were estimated to evaluate the clinicopathological difference of PD-L1+ group and PD-L1- group. We used funnel plot and Egger’s test, as well as Begg’s test to assess the publication bias. The P values are two-sided. The significance level was set to be 5%. The statistical analysis was finished using STATA 13.0 (StataCorp, College Station, Texas, USA).


Search results

192 manuscripts were selected according to the search strategy. From the title and abstract review, 182 of the articles were excluded due to non-English papers, non-human experiments, non-breast cancer related studies, non-prognostic researches or non-original articles (e.g. review, letter, case report). Finally, a total of 10 studies were included in the main meta-analysis of PD-L1 and survival, while, 7 for clinical pathological features and PD-L1.

Study selection and characteristics

All features of the 10 eligible studies are listed in Table 1 [8-15,17- 18]. Clinical pathological feature use 7 studies from them listed in Table 2. The publication years of the eligible studies ranged from 2014 to 2015. The number of patients in each study ranged from 192 to 5454. The quality of the enrolled studies varied from 5 to 8, with a mean of 7. The clinicopathological features including tumor size, nodal statues, histological grade and (estrogen receptor/progestogen receptor/human epidermal growth factor receptor) ER/PR/HER-2 statues. PD-L1 expression levels were measured in tumor tissue. In addition, tissue immunochemistry staining (IHC) for PD-L1 expression was utilized in 8 studies. The remaining two study applied mRNA technology to detect PD-L1 expression (Table 1). In all studies, none of the patients received neo-adjuvant radio- or chemo-therapy prior to surgery.

Author Year N Evaluation HR LCI UCI Outcome
Qin 2015 870 IHC 1.788 1.195 2.674 OS
Baptista 2015 192 IHC 0.3 0.09 0.94 OS
Park 2015 333 IHC 2.08 0.86 5.04 OS
Muenst 2014 650 IHC 3.063 2.318 4.047 OS
Sabatier 2014 5454 DNA microarray 0.52 0.35 0.77 OSS
Qin 2015 870 IHC 1.386 1.003 1.916 DFS
Baptista 2015 192 IHC 0.84 0.39 1.83 DFS
Park 2015 333 IHC 1.21 0.56 2.62 DFS
Schalper 2014 398 (YTMA201) QIF 0.268 0.099 0.721 RFS
Sabatier 2014 5454 DNA microarray 0.55 0.38 0.79 MFS

Table 1: The basic information for each study [13,15117].

Study Author Detection Method Year
1 Schalper (398(YTMA201)) QIF 2014
2 Qin IHC 2015
3 Baptista IHC 2015
4 Park IHC 2015
5 Cimino-Mathews IHC 2015
6  Muenst IHC 2014
7 Sabatier DNA microarray 2014

Table 2: Clinical pathological feature studies [13,15,17].

Main results

Since the researches use different index for survival (OS/OSS/ DFS/MFS/RFS), as shown in Table 3, we divided them into 4 groups. However, we found that elevated PD-L1 had no significant association with breast cancer patients’ survival (Figures 1a-1d).

Index TYPE Meta-analysis Heterogeneity test Model Publication bias (P value)
HR 95%CI z value P value I2 Q value P value Begg's test Egger's test
A OS 1.640 0.852 3.160 1.48 0.139 82.5% 17.14 0.001 Random 0.308 0.187
B OS+OSS 1.194 0.517 2.757 0.42 0.677 93.4% 60.42 <0.001 Random 0.806 0.439
C DFS 1.276 0.966 1.686 1.72 0.086 0.0% 1.39 0.498 Fixed 0.296 0.370
D DFS+MFS+RFS 0.776 0.444 1.353 0.90 0.371 80.1% 20.08 <0.001 Random 0.462 0.566

Table 3: The result of meta-analysis.

Figure 1: Analysis of PD-L1positive versus PD-L1 negative on tumor cells of breast cancer patients in terms of survival (OS/OS+OSS/DFS/DFS+MFS+RFS).

However, in the analysis of the clinical pathological feature, we can see the relationship between elevated PD-L1 and clinicopathological parameters in Table 4. In breast cancer, increased PD-L1 was found to be significantly associated with histological grade (OR=1.86, 95% CI: 1.38-2.51; Pheterogeneity=0.0196) (Table 4 and Figure 2a), ER (OR=0.36, 95% CI: 0.17-0.75; Pheterogeneity=0.000) (Figure 2b), PR (OR=0.31, 95% CI: 0.11-0.86; Pheterogeneity=0.000) (Figure 2c). No significant relationship was detected between PD-L1 overexpression and other clinical characteristics in breast cancer due to limited studies.

VAR Meta-analysis Heterogeneity test Model Publication bias (P value)
OR 95%CI z value P value I2 Q value P value Begg's test Egger's test
AGE 0.91 0.78 1.06 1.24 0.2160 41.63 1.71 0.1906 Fixed 1.0000 NA
TumorSize 1.33 0.92 1.92 1.49 0.1356 75.42 20.35 0.0011 Random 0.7071 0.9632
Nodal 1.37 0.98 1.91 1.82 0.0687 80.26 25.32 0.0001 Random 0.2597 0.3878
Histologic 1.86 1.38 2.51 4.05 0.0001 62.78 13.43 0.0196 Random 1.0000 0.3907
ER 0.36 0.17 0.75 2.73 0.0064 95.39 86.72 0.0000 Random 0.4624 0.7512
PR 0.31 0.11 0.86 2.25 0.0243 96.36 55.00 0.0000 Random 1.0000 0.6890
HER-2 1.22 0.85 1.73 1.08 0.2822 60.96 12.81 0.0253 Random 0.7071 0.7838
Ki67 1.16 0.51 2.68 0.36 0.7221 95.16 62.01 0.0000 Random 1.0000 0.2353
Luminal 1.39 0.74 2.62 1.02 0.3061 81.67 10.91 0.0043 Random 1.0000 0.6900

Table 4: The result of meta-analysis.

Figure 2: Analysis of PD-L1positive versus PD-L1 negative on tumor cells of breast cancer patients in terms of histological grade/ER/PR.

Publication bias

The Begg’s funnel plot did not show any evidence of obvious asymmetry. Then, the Egger’s linear regression was performed and publication bias was not detected either (Tables 3 and 4).


Recently studies suggest that determination of PD-L1 status on tumor cells could help select patients for novel anti- PD-1/PD-L1 therapies [22]. However, the association of the expression of PD-L1 and breast cancer patients’ prognosis remains unclear, including the exact relationship between PD-L1 and clinicopathological features. Thus, a meta-analysis incorporating all available data from correlative studies is a reasonable method by which to address these questions. Our study show PD-L1 had no significant association with breast cancer patients’ survival. However, the prognosis of many other carcinomas, including non-small-cell lung cancer, gastrointestinal tract cancer, melanoma, show association with PD-L1. We think there must be some reasons, listed below, except for the heterogeneity.

First, in evaluation and criteria for PD-L1 expression we could see that studies using IHC evaluation show PD-L1 related to poor prognosis, however, researches using mRNA evaluation show PD-L1 related to better prognosis. These two techniques have their own drawbacks. For IHC, the accurate determination of PD-L1 protein levels in the tumor samples through IHC is limited by the reliable antibodies, absence of validated assays and interpretative uncertainties for example, the cutoff value. While, the mRNA evaluation includes the case that PD-L1 didn’t express on the cell surface. So which technique will be used for PD-L1 expression determination need more research? Anyway, so far, most of the researches for PD-L1 and breast cancer are done by IHC.

Second, the different cut-off value of PD-L1 show different PD-L1 rate and relationship with clinical pathological features. Since IHC evaluation methods and cut-off values were not consistent for breast cancer, the comparison gives a completely opposite result. Why the different evaluation and criteria can give the opposite result? This may be an explanation of the mechanism. PD-L1 related immune escape was considered the reason for breast cancer poor prognosis. However, for the survival benefit of PD-L1+ carcinoma breast cancer patients, the explanation could be the presence of a strong antitumor immune response triggered by PD-L1 up regulation [14]. One research show that PD-L1 expression of tumor cells was due to the activation of CD8-positive T cells. Then, the CD8-positive T cells release several cytokines. Through this way, the PD-L1 expression in tumor cells was up regulated by the immune system [18]. From this point, whether PD-L1 can give a poor or better prognosis, whether PD-L1 can trigger immune escape or antitumor immune response due to the PD-L1 expression rate. And a standard PD-L1 cut-off value is essential in PD-L1 expression determination.

Third, different patient subtypes (ER/PR+, HER2+ or TNBC) receive different treatments, which by themselves have different prognosis. However, there is lack of researches on PD-L1 of different subtypes and breast cancer prognosis. We need more researches on correlates of prognosis within a particular subgroup, as illustrated by Klinke [23]. As PD-L1 expression correlates with an on-going anti-tumor immune response, these different molecular subtypes also have a different propensity to engage anti-tumor immunity. For instance, HER2+ overexpression has been reported to down regulate components of the MHC class I antigen-presentation [24].

While, increased PD-L1 was found to be significantly associated with histological grade, ER and PR the histological grade association can be a clue for the relationship between PD-L1 and immune escape, which is the essence of PD-L1. While, we need further more investigation to verify relationship between ER, PR and PD-L1 and their interaction more specific studies on molecular subtype and PDL1 will made the target therapy more specific.


Despite some trends observed, we currently cannot draw a valid conclusion that PD-L1 status is a predictor of prognosis for patients with breast cancer. We should deeply explore the mechanism related to PDL1 expression rate, immune escape and antitumor immune response. Further, develop an evaluation standard for PD-L1 expression which can exactly give the prediction of whether PD-L1 can trigger immune escape or antitumor response. What’s more conduct the researches on different molecular subtype. So that make clear whether the PD-L1 related drugs can be used clinically for the very type of breast cancer patients. And not only PD-L1 antibodies but also PD-L1 analogue.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Recommended Journals

Recommended Conferences

Article Usage

  • Total views: 328
  • [From(publication date):
    August-2017 - Jun 19, 2018]
  • Breakdown by view type
  • HTML page views : 297
  • PDF downloads : 31

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

nur[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7